Introduction
Antiphospholipid syndrome (APS) is characterized by the occurrence of thrombosis and/or pregnancy morbidity associated with the persistent presence of antiphospholipid antibodies (aPLs). Thrombocytopenia is one of the non-criteria manifestations of APS [1] . The prevalence of thrombocytopenia in APS patients has been reported to be between 20% and 53% [2] , which is higher than that in patients with other autoimmune diseases. In addition, a multicenter prospective study consisting of 1000 APS patients from 13 European countries reported that 8.7% of the patients newly developed thrombocytopenia during a 10-year follow-up period [3] . Thrombocytopenia in APS patients is, however, mostly mild, i.e. > 50 9 10 3 lL -1 , and does not require therapeutic interventions to prevent bleeding events. The pathologic mechanism underlying these unique clinical characteristics remains unclear [4] [5] [6] .
In patients with idiopathic/immune thrombocytopenia (ITP), aPLs increased the risk of thrombotic events, with 5-year thrombosis-free survival of only 39%, which is significantly lower than the 97.7% seen in aPL-negative patients [7] . However, it remains to be elucidated whether thrombocytopenia 'paradoxically' increases the risk of thrombosis in aPL carriers [8] .
In this study, we evaluated the impact of platelet count in terms of predicting thrombotic events in both aPLpositive and aPL-negative patients. Furthermore, we stratified the risk of thrombosis in aPL-positive patients by combining platelet count and antiphospholipid score (aPL-S), which represents a quantification of aPL varieties and titers [9] .
Methods

Study population
This was a single-center, retrospective, longitudinal study comprising 953 consecutive patients who were suspected of having autoimmune disease at Hokkaido University Hospital between January 2002 and December 2006. Among these 953 patients, 262 had been followed up for < 2 years, owing to both completion and loss of followup, and were excluded from the analysis. The median follow-up period for the 691 eligible patients was 128 months. In patients with thrombosis, follow-up for the study was completed at the time of the first vascular event. The historical profiles, clinical manifestations and diagnoses were carefully obtained by review of the medical records or by interviewing the patients. A low platelet count was defined as a count of < 150 9 10 3 lL -1
, the 2.5th lower percentile of the normal platelet count distribution [10] , at the time of aPL testing. Arterial thrombotic events comprised stroke, myocardial infarction, iliac artery occlusion and mesenteric artery thrombosis as confirmed by computed tomography scanning, magnetic resonance imaging, or conventional angiography. Venous thrombotic events comprised deep vein thrombosis and pulmonary thromboembolism confirmed by computed tomography scanning, angiography, or scintigraphy.
Determination of aPL and aPL-S Anticardiolipin antibodies (IgG and IgM) were assayed according to the standard ELISA [11] . Anti-b 2 -glycoprotein I (b 2 GPI) antibodies (IgG and IgM) were assayed by in-house ELISA, as previously reported [12] . Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PTs) (IgG and IgM) were assayed by in-house ELISA with the phosphatidylserine-prothrombin complex as antigen [13] . For the detection of lupus anticoagulant (LA), the guidelines recommended by the Subcommittee for Standardization of the ISTH were followed [14] . aPL-S was calculated from 0 to 86, as previously described [9] .
Statistical analysis
Categorical variables are expressed as percentages, and continuous variables are expressed as mean AE standard deviation for those normally distributed, or otherwise as medians and interquartile ranges. Statistical analysis was performed with the Mann-Whitney U-test, Fisher's exact test, or Dunnett's test, as appropriate. Correlation coefficients were assessed with the Spearman rank method. The Kaplan-Meier survival estimates were stratified by the optimal cut-off values and compared with log-rank tests.
P-values of < 0.05 were considered to be significant. All statistical analyses were performed with GRAPHPAD PRISM 7 (Graphpad Software, San Diego, CA, USA).
Results and discussion
First, we investigated the relationship between aPLs and platelet count by using a cross-sectional analysis. Of 691 patients enrolled in this study, 238 had systemic lupus erythematosus (SLE), 110 had rheumatoid arthritis, 38 had primary APS, 33 had vasculitis syndrome, and 26 had polymyositis/dermatomyositis. At least one aPL was found to be positive in 42.1% (291/691) of patients at the time of enrollment. The prevalence of low platelet count was higher in aPL-positive than in aPL-negative patients (14.1% [43/291] versus 9.5% [38/400], P = 0.041). Among the 219 aPL-positive patients, LA and aPS/PTs were significantly more prevalent in patients with low platelet counts than in those without (Table 1) . Furthermore, aPL-S was significantly higher in patients with low platelet counts than in those without. We also evaluated the correlation between aPL-S and platelet count by using the Spearman rank method, and a negative correlation was observed with statistical significance (Fig. 1) . Among the 400 aPL-negative patients, low platelet counts were more frequently observed in SLE patients (Table 1) . Next, we evaluated the impact of low platelet count on the development of thrombotic events by a longitudinal follow-up in both aPL-positive and aPL-negative patients. Included were any thrombotic events that had developed from the day of aPL testing until the last day of followup. During the follow-up period (median of 128 months, IQR 76-148 months), thrombosis developed in 53 of 691 patients (32 arterial and 21 venous thrombotic events). Among aPL-positive patients, patients with low platelet counts developed thrombosis more frequently than those without (2.34 versus 0.96 per 100 person-years, P = 0.021). Among aPL-negative patients, in contrast, there was no difference in the rate of thrombosis development between patients with and without low platelet counts (0.89 versus 0.54 per 100 person-years, P = 0.423) (Fig. 2A) . As 34% (238/691) of the enrolled patients had SLE, we performed a subgroup analysis in SLE and non-SLE patients. Regardless of whether or not patients had SLE, patients who had both aPLs and low platelet counts had a high risk of developing thrombosis in (Fig. 2B) . Furthermore, subgroup analysis for other thrombotic risk factors, including age, smoking, hypertension, dyslipidemia, diabetes mellitus, and past history of thrombosis, showed similar results (data not shown). The KaplanMeier estimates also showed the relationship between platelet count and thrombosis in aPL-positive but not in aPL-negative patients (Fig. 3A,B) . Finally, to further assess the platelet count-thrombosis relationship in aPL-positive patients, we divided aPLpositive patients into two subgroups according to the levels of aPL-S. Among 242 low-aPL-S patients (0 < aPL-S < 30), patients with low platelet counts developed thrombosis more frequently than those without. In contrast, 48 high-aPL-S patients (aPL-S ≥ 30) developed thrombosis frequently, regardless of the platelet count (Fig. 3C,D) . These findings indicate the potential to stratify the risk of developing thrombosis in aPL carriers by combining platelet count and aPL-S. These results were similar even if a low platelet count was defined as < 100 9 10 3 lL -1
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, which was the criterion used for the diagnosis of ITP [15] (data not shown).
Although previous cohorts have shown a high prevalence of thrombocytopenia in patients with APS as compared with other autoimmune diseases [2] , the underlying pathologic mechanism remains to be elucidated. In ITP patients, the presence of aPLs has been shown to be a thrombotic risk factor by a prospective cohort study [7] and, more recently, by a systematic review [16] . Our data indicate that a low platelet count is a risk factor for developing thrombosis in aPL carriers. Conversely, a retrospective study performed by Krause et al. showed a similar prevalence of thrombotic episodes in APS patients with and without thrombocytopenia [17] . One of the possible reasons for the discrepancy is that our study enrolled patients with various autoimmune diseases, including APS and non-APS, whereas the study by Krause et al. enrolled APS patients only. Another reason may be the inclusion of aPL-S in our study. KaplanMeier estimates in our study showed a similar risk of developing thrombosis in high-aPL-S (aPL-S ≥ 30) patients with and without low platelet counts.
To date, four different mechanisms have been suggested to underlie thrombocytopenia with aPLs; platelet activation with subsequent destruction, decreased platelet production, increased platelet pooling, and pseudothrombocytopenia [5] . Of these potential mechanisms, platelet activation by aPLs and destruction of platelets by antibodies directed against their membrane glycoproteins (GPs) may particularly be linked to the risk of developing thrombosis. Some studies have shown that aPLs induce the expression of platelet membrane GPs, especially GPIIb-IIIa [18] . Platelet activation occurs after the binding of anti-b 2 GPI-dimerized b 2 GPI complex to platelet surface membrane GPs in vitro [19] . A previous report showed that thrombocytopenia in patients with aPLs was associated with high titers of antibodies against platelet GPIb-IX and GPIIb-IIIa [20] . It is of particular importance that platelet counts increase following the administration of antiplatelet agents in some APS patients [21] , presumably by decreasing the expression of GPs and subsequently inhibiting the binding of anti-b 2 GPI-dimerized b 2 GPI complex on platelet surfaces.
Given the lack of evidence on which to recommend or advise against primary prophylaxis for thrombosis in aPL carriers [22] , precise risk stratification of thrombosis is currently an unmet need in such individuals. Our previous study has already shown high aPL-S (aPL-S ≥ 30) to be an independent risk for thrombosis [9] . Conversely, low aPL-S (0 < aPL-S < 30) was not identified as a thrombotic risk, and was even similar to the absence of aPLs in terms of predicting future thrombotic events [9] . The current data, by combining platelet count and aPL-S, can be used to extract individuals with a high thrombotic risk from those 'low aPL-S carriers'.
The results of this study are subject to some limitations. First, this is a single-center retrospective study comprising only Japanese patients. With such a design, antithrombotic agents are selected according to physicians' decisions, leading to a grouping bias. Second, aPL testing, which was one of the patient inclusion criteria in this study, was performed according to physicians' decisions, suggesting a selective bias.
In summary, our data provide the first evidence of thrombotic risk stratification by platelet count in patients with aPLs. A low platelet count is associated with aPLs, and particularly with aPL-S, in autoimmune disease patients, and the presence of a low platelet count or high aPL-S is a risk factor for the development of thrombosis in aPL carriers. These findings provide new insights into the management of APS, aPL carriers, and ITP, and also contribute to the understanding of the pathophysiology of APS.
Addendum
R. Hisada and M. Kato had full access to the database, performed statistical analysis, interpreted the data, and drafted the manuscript. E. Sugawara and Y. Fujieda supervised statistical analysis, interpreted the data, and revised the manuscript. K. Oku and T. Bohgaki interpreted the data and revised the manuscript. O. Amengual and S. Yasuda helped in the design of the study and critically reviewed the manuscript. T. Atsumi had full access to the database, performed statistical analysis, interpreted the data, and revised the manuscript.
